| 于俊民 张小波 李大鹤 胡爽 王慧冬 仝颖 王凌云.厄贝沙坦对老年非ST 抬高型心肌梗死者TGF-β1、CTGF的影响*[J].,2016,16(28):5549-5551 |
| 厄贝沙坦对老年非ST 抬高型心肌梗死者TGF-β1、CTGF的影响* |
| Effects of Irbesartan on the SerumTGF-β1 and CTGF levels in ElderlyPatients with Non-ST-elevation Myocardial Infarction |
| |
| DOI： |
| 中文关键词: 厄贝沙坦 老年 非ST 抬高型心肌梗死 转化生长因子-β1 结缔组织生长因子 |
| 英文关键词: Irbesartan Elderly patients NSTEMI TGF-β1 CTGF |
| 基金项目:黑龙江省自然科学基金项目（H201389） |
|
| 摘要点击次数: 782 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：探讨厄贝沙坦对老年非ST 抬高型心肌梗死(NSTEMI) 患者血清转化生长因子-β1 (TGF-β1) 与结缔组织生长因子
(CTGF)水平的影响。方法：选择我院2013 年10月-2014 年05 收治的诊断明确为NSTEMI的患者38 例，将因各种原因不能服用
厄贝沙坦者作为对照组(n=17)，余为药物组(n=21)。入院后，两组患者均给予常规治疗(抗血小板、抗凝、调脂、单硝酸异山梨酯注射
液等)，药物组加服厄贝沙坦150 mg，1 次/ 日，应用2 周。分别于治疗前、治疗后第7、14 天抽取患者空腹静脉血，采用ELISA法检
测患者血清TGF-β1、CTGF 水平。结果：治疗第7 天时，两组患者血清TGF-β1、CTGF水平均高于治疗前(P<0.05，p<0.01)，但两组
间比较差异无统计学意义(P>0.05)；治疗14 天时，两组患者血清TGF-β1、CTGF 水平均较第7 天降低(P<0.01)，且药物组血清
TGF-β1、CTGF 水平低于治疗前(P<0.05, p<0.01)，对照组血清TGF-β1 水平高于治疗前(P<0.05)，药物组TGF-β1 水平低于对照组
(P<0.05)，差异均有统计学意义，而两组之间血清CTGF水平比较差异无统计学意义(P>0.05)。结论：厄贝沙坦可使NSTEMI患者
血浆中TGF-β1 水平受到抑制，虽能使CTGF 水平下降，但作用不明显。 |
| 英文摘要: |
| Objective:To investigate the effects of Irbesartan on the serum TGF- β1, CTGF levels of elderly patients with
non-ST-elevation myocardial infarction (NSTEMI), and explore the possible mechanisms.Methods:Thirty-eight cases of elderly
NSTEMI patients admitted in our hospital from 2013.10 to 2014.05 who couldn't take Irbesartan were choosen into the control group,
while the others were enrolled in the drug group. The control group (n=17) received conventional therapy (nitric acid ester, Antiplatelet,
anticoagulant, lipid-lowering therapy, etc) and the drug group (n=21) was given conventional therapy plus Irbesartan (150mg/d), the
therapy lasted for 2 weeks. The serum TGF-β1, CTGF levels were measured by ELISA before and on the 7th, 14th day after treatment
respectively.Results:On the 7th day after treatment, the serum TGF-β1, CTGF levels of both groups were higher than those before
treatment (P<0.05, P<0.01), but no statistically significant difference was found between two groups (P>0.05). On the 14th day after
treatment, the serum levels of TGF-β1, CTGF of both groups were lower than those on the 7th day after treatment (P<0.01), and the
serum levels of TGF-β1, CTGF in drug group were obviously lower than those before treatment (P<0.05, P<0.01), the serum level of
TGF-β1 in the control group was higher than that before treatment and the drug group(P<0.05), but no significant difference was found in
the serum level of CTGF between two groups (P>0.05).Conclusion:Irbesartan could inhibit the serumTGF-β1 level of elderly patients
with NSTEMI, but had little effect on the serumCTGF. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
